

# **How long will treatment guidelines for tuberculosis continue to overlook variability in drug exposure?**

Morris MULIADITAN<sup>1,2</sup>, Oscar DELLA PASQUA<sup>1,2\*</sup>

<sup>1</sup>UCL School of Life and Medical Sciences, London, United Kingdom.

<sup>2</sup>GlaxoSmithKline, London, United Kingdom.

Running title: **Determinants of exposure variability in tuberculosis**

## **Corresponding author\*:**

Oscar Della Pasqua

BMA House

Tavistock Square

London, United Kingdom

WC1J 9JP

**Phone:** 020 78741544

**Email:** o.dellapasqua@ucl.ac.uk

Abstract word counts: **250** [max 250]

## SYNOPSIS

**Background:** Despite wide clinical acceptance, the use of weight-banded dosing regimens for the treatment of tuberculosis in adults has been defined on an empirical basis. The potential impact of known covariate factors on the exposure to the different drugs has not been taken into account.

**Objectives:** To evaluate the effect of demographic factors on the exposure to standard of care drugs after weight-banded dosing, as currently recommended by tuberculosis treatment guidelines. In addition, we aim to identify alternative dosing regimens that ensure comparable systemic exposure across the overall patient population

**Methods:** Clinical trial simulations were performed to assess the differences in systemic exposure in a cohort of virtual patients. Secondary pharmacokinetic parameters were used to evaluate the adequacy of each regimen along with the percentage of patients achieving predefined thresholds.

**Results:** Our results show that patients below 40 kg are underexposed relative to patients with higher body weight. The opposite trend was observed following crude weight band-based dosing regimen with 50 kg as cut-off point. Simulations indicate that a fixed dose regimen based on three (<40 kg), four (40-70 kg) or five (>70 kg) tablets of 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide and 275 mg ethambutol reduces variability in exposure, increasing the overall probability of favourable long-term outcome across the population.

**Conclusions:** These findings suggest the need to revisit current guidelines for the dose of standard of care drugs for tuberculosis treatment in adults. The proposed fixed dose regimen should be considered in future clinical trials.

## INTRODUCTION

The WHO and International Union Against Tuberculosis and Lung Disease (IUATLD) have published guidelines for treatment of tuberculosis (TB) which include recommendations for standardized first-line dosing regimens <sup>1, 2</sup>. Although considerably effective in clinical trial settings, the rationale underpinning dosing regimens of modern short-course therapy have been empirical <sup>3</sup>. As a result, the dosing regimens that are currently used for TB treatment have never been optimized taking into account the known sources of variability in the pharmacokinetics (PK) of each drug. Consequently, the implications of variability in exposure for the evaluation of efficacy after treatment over periods shorter than 6 months has not been considered in recent clinical trials.

The lack of consensus regarding the optimal regimen and limited evidence on the impact of different regimens on the efficacy and safety profile of the standard of care drugs may partly explain the discrepancies in the choice of dosing regimens used in current clinical practice. Moreover, there are no data showing that each of these regimens warrants comparable exposure across the trial population. A few studies in the published literature have focused on the evaluation of PK variability of first-line drugs across the WHO weight bands <sup>4-8</sup>. A correlation between weight and drug concentrations was found in all analyses, implying that patients with lower body weight will be exposed to lower drug levels despite the use of weight band-based dosing regimens. These findings support the need to revisit the current dosing recommendations <sup>9</sup>.

Growing evidence suggests that the currently recommended dosing regimens are sub-optimal <sup>10-13</sup>. Assessing the impact of different regimens on drug exposure variability across weight bands used in TB treatment would however require a complex, expensive and ethically

complex clinical study. In fact, considering the reality of poverty-related diseases and the limited funding available, such clinical trials are unlikely to be conducted in the near future.

Nevertheless, such limitations should not prevent us from evaluating and optimizing the dose rationale for the first-line treatment of TB. In fact, this has been one of the focus of the clinical debate regarding the effective use of antibiotics for more than a decade, as it represents the most direct method for improving treatment outcome, potentially allowing for shorter intervention and tackling resistance <sup>14</sup>.

The aim of present study was therefore to evaluate the implications of different dosing regimens for all four drugs used as standard of care in adults taking into account the effect of body size on systemic drug exposure. Whereas pharmacodynamic (PD), immunological and microbiological aspects also contribute to variability in response, the ultimate goal of this analysis was to minimize the impact of differences in drug disposition by identifying the optimal ratio for standard care fixed dose combination (FDC) regimens that ensure comparable systemic exposure across the patient population.

## **METHODS**

### **Patient population**

Individual datasets from five clinical studies were obtained from the Innovative Medicines Initiative (IMI) funded PreDiCT-TB consortium and three clinical studies from the Critical Path to TB Drug Regimens (CPTR) database. The Critical Path to TB Drug Regimens initiative is a public-private partnership launched in March 2010 by Critical Path Institute, the Bill & Melinda Gates Foundation and the Global Alliance for TB Drug Development (TB Alliance). The baseline demographic characteristics of the patient population in each study is summarised in **Supplementary Material (Table S1)**. Age, weight, height and sex were the covariates of interest. Only patients who were between 18 and 65 years of age were included in the analysis. Patients who were HIV positive or had unknown HIV status were excluded. The final patient population for the PK simulations will be referred as “trial population” onwards.

### **Population pharmacokinetic analysis**

Published PK models of rifampicin <sup>15</sup>, isoniazid <sup>16</sup>, pyrazinamide <sup>17</sup> and ethambutol <sup>18</sup> were used to simulate concentration versus time profiles during the intensive phase of TB treatment (**Supplementary Material, Figure S1**). The chosen PK sampling times were: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post dose. No changes with respect to the model structure (i.e. random and fixed effect, or covariate effect) were made. An exception was made with regard to inter-occasion variability (IOV). These parameters were excluded in our analysis to minimize study-related bias in the simulated PK variability. Sources of parameter variability in the simulations were hence derived from inter-individual variability and covariate effect. Size was included as covariate for clearance (CL/F) in all PK models, either

using weight (isoniazid, pyrazinamide, and ethambutol) or normal fat mass (NFM; rifampicin). NFM can be predicted from sex, weight and height as per described by Holford and Anderson<sup>19</sup>. NAT2 genotype was an additional covariate for CL/F in the isoniazid PK model. PK simulations were performed in the trial population (200 trial simulations) to assess the magnitude of the differences in drug exposure following currently recommended dosing regimens, as well alternative regimens identified in present analysis.

### **Assessment of PK variability following the current dosing regimens**

Considering that systemic exposure is likely the most relevant index for efficacy<sup>20, 21</sup>, area under the plasma concentration-time curve ( $AUC_{0-24}$ ) at steady state was derived following dosing regimens based on WHO guidelines and crude weight band where 50 kg was chosen as cut-off value. According to WHO guidelines<sup>2</sup>, patients in respectively <40 kg, 40-54 kg, 55-70 kg or >70 kg weight band received a daily fixed dose of 2, 3, 4 or 5 tablets of 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide and 275 mg ethambutol for 2 months. Patients treated with crude weight band-based regimen were given a daily fixed dose of either 3 (<50 kg) or 4 tablets ( $\geq 50$  kg). The trapezoidal rule was used to calculate  $AUC_{0-24}$ . Taking into account accepted variation due to differences in formulation<sup>22</sup>, variation in exposure across weight bands was considered acceptable if the average  $AUC_{0-24}$  did not vary by more than 20% (80-120%) relative to the highest WHO weight band (>70 kg), which was treated as reference. At last, the relationship between weight, CL/F and drug exposure was evaluated to demonstrate the contribution of body size on PK variability.

## Software

The statistical software R (version 3.2.5) <sup>23</sup> was used for data preparation, data analysis, statistical and graphical summaries. NONMEM 7.3 <sup>24</sup> was used to simulate concentration versus time profiles.

## RESULTS

### Patient population

2231 patients (676 female and 1555 male) were included in this analysis. Baseline characteristics of this main population is summarised in **Table 1**. The median height stratified by sex and WHO weight band population (**Supplementary Material, Table S2**) was imputed for respectively 123 female (5.5%) and 275 male patients (12.3%) for whom NFM (a covariate in the rifampicin PK model) otherwise could not be calculated due to missing height. The distributions of the continuous covariates of interest in the trial population are presented in **Figure 1**.

### PK variability associated with currently recommended dosing regimens

AUC<sub>0-24</sub> at steady state was derived from the simulated concentration-time profiles at the end of the intensive phase. Dosing regimens based on WHO recommended weight bands (<40kg, 40-54kg, >54-70kg and >70kg) yielded highly variable exposure across the population (**Figure 2**). Subjects who weighed less than 40 kg appeared to be under-dosed when compared to the rest of the population and displayed on average more than 20% lower AUC<sub>0-24</sub> as compared to patients in the highest WHO weight band (**Figure 3**). Conversely, comparable exposure between patients weighing up to 70 kg was achieved when using a crude weight band in which 50 kg was used as cut-off value (**Figure 2**). However, in this case under-dosing occurred in

patients in the highest weight band (>70 kg), wherein the simulated  $AUC_{0-24}$  was on average more than 20% lower than to patients weighing less than 40 kg (**Figure 3**). This finding was rather expected as heavier patients received less than WHO recommended dosage (4 instead of 5 tablets).

### **Proposal for an adjusted weight-banded dosing regimen**

The weight-band based dosing regimen that yields comparable exposure range across the population is presented in **Table 2**. Based on this regimen, patients weighing less than 40 kg were given 3 instead of 2 FDC tablets where patients between 40 and 54 kg received 4 (instead of 3) FDC tablets. Simulations revealed that the use of the proposed regimen resulted in considerably lower variation in drug exposure (<20%) across the population (**Figures 2 and 3**).

### **Assessment of body size-specific effect on exposure variability**

Our analysis showed that currently recommended dosing regimens fail to take into account the nonlinear relationship between body size and drug clearance (**Figure 4**). Using rifampicin as example, **Figure 4** showed that rifampicin CL/F (per kg body weight) in patients weighing <40 kg were in fact on average 1.2-fold faster than patients weighing >70 kg. Similar observations were found for isoniazid, pyrazinamide and ethambutol as well. Consequently, these results demonstrate that a more than proportional dose change is needed for standard of care drugs, especially for patients in the lowest weight-band, to account for the higher clearance per kg body weight.



## DISCUSSION

Our results show that despite the use of weight bands, the recommended dosing regimens do not correct for the influence of body size on drug disposition. None of the currently used regimens yields satisfactory exposure variability across all the population of TB patients. The use of clinical trial simulations showed that currently recommended dosing regimens result in wide variation in drug exposure across patients with different body weight. The usage of a crude weight band based on 50 kg cut-off value seemed to improve the variability in exposure in patients up to 70 kg but simultaneously yielded lower exposure levels in patients at the highest weight band. Such differences in exposure can contribute to treatment failure and should not be overlooked. Of interest is the implications for patients in the lowest weight band (<40 kg), whom according to our analysis, appears to be underexposed when treated according to the WHO weight banded regimens. Indeed, studies have found an association between low bodyweight and unsuccessful treatment outcome or delayed culture conversion<sup>25-27</sup>.

The current dosing recommendations assume a linear correlation between weight and drug elimination whereas a nonlinear relationship between body weight and systemic exposure can be observed for many drugs<sup>28</sup>. Such nonlinearity was clearly demonstrated in our analysis. A nonlinear correlation between body weight and drug clearance has been found for numerous compounds, supporting the importance of acknowledging this relationship when defining doses and dosing regimens<sup>28</sup>.

### **Reducing variability in drug exposure is critical for the optimisation of treatment response**

A fixed dosing regimen of 3 (<40 kg), 4 (40-70 kg) and 5 tablets (>70 kg) of 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide and 275 mg ethambutol was found to yield the desired

target drug exposure as compared to standard WHO regimen whilst reducing overall variability of all first-line drugs. The proposed increase in the doses of all four drugs for patients below 54 kg is expected not to lead to a higher increase in adverse events as was shown recently with higher doses of rifampicin <sup>11</sup>.

We acknowledge that better target exposure achievement, efficacy and potentially shorter treatment duration may require much higher doses than is currently prescribed <sup>11, 29</sup>. Nonetheless, reducing variability is in itself an important step in improving therapeutics. We have identified an optimal ratio for standard care FDC regimen that has the potential to immediately benefit TB patients. On the long term, we envisage that addition of higher doses of key sterilizing drugs such as rifampicin or pyrazinamide to our proposed dosing regimen will lead to a truly optimized TB treatment as a result of maximising efficacious exposure and minimizing PK variability across the patient population.

We also acknowledge that currently used weight band cut-offs may not be optimal for reducing variability in exposure. On the other hand, given these cut-offs have been used in clinical practice for a long time, we believe that adhering to currently used weight groups would facilitate the implementation of the proposed dose recommendation.

### **Limitations**

Our analysis has several limitations. First, only a small fraction of the patient population that were included was below 40 kg (2.1%) which might be lower than in real setting. A survey performed in 2001 as part of the National TB programme in Kenya, Nepal and Senegal (n=8640) showed that the fraction of patients weighing below 40 kg could be approximately as much as 30% <sup>30</sup>.

Second, the PK models we used were developed based on relatively small number of patients. As such, we may have imposed factors on our predicted drug that may have been specific to those studies only (such as formulation effects or genetic variants). The PK models did not include additional covariates that may also be relevant for PK variability such as genotype (except for isoniazid), race or other co-morbidities (e.g., HIV). Consequently, we were not able to take into account the potential effect of covariates other than size and/or sex on PK variability in our proposed dosing regimen. The effect of genotype on isoniazid PK has been evaluated earlier<sup>16</sup> and was therefore not explored in detail in this analysis. Most importantly, we have not included HIV patients into the analysis, who are affected by drug-drug interactions (DDI) with antiretrovirals<sup>31, 32</sup>. Further assessment on the role of antiretrovirals for dose optimization in TB-HIV patients is the scope of a future investigation by our group.

Finally, we recognise that the limited microbiological and clinical cure data may weaken the inferences regarding the impact of underexposure to standard of care drugs, i.e., that those patients are effectively at a higher risk of treatment failure or relapse. Given that current first-line treatment can already achieve as much as 83% success rate<sup>33</sup>, further testing of this hypothesis would be desirable to demonstrate that PK factors may partly explain the observed efficacy rates, especially if one considers that the frequency of low body weight patients in the real population is far larger than those enrolled in clinical trials<sup>30</sup>.

In conclusion, the impact of body size on PK variability highlights the relevance of discriminating patient from drug-related factors during the development of novel treatments for TB. Clinical trial simulations showed that regimens based either on the currently recommended WHO weight bands or crude weight bands lead to inadequate drug exposure variability across the population. By contrast, an adjusted fixed dose regimen based on three

(<40 kg), four (40-70 kg) or five (>70 kg) tablets of 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide and 275 mg ethambutol was shown to reduce the variability in systemic exposure. This may have direct implications for efficacy rates and long-term outcome across the population. Our findings suggest the need to revisit current guidelines on the use of standard of care drugs for TB.

## **ACKNOWLEDGMENT**

The authors would like to thank Oxford University Clinical Research Unit (funded by the Wellcome Trust), Janssen, Novosibirsk Tuberculosis Research Institute, and the TB Research Unit at Case Western Reserve University (established with funds from the United States National Institutes of Allergy and Infectious Diseases, National Institutes of Health and Human Services, under Contract No. NO1-AI95383 and HHSN266200700022C/NO1-AI-70022) for their contribution in providing individual patient data to the PreDiCT-TB database. The authors are also thankful to Critical Path to TB Drug Regimens (CPTR) for providing data used in the preparation of this article. The investigators within CPTR contributed to the design and implementation of the CPTR Database and/or provided data but did not participate in the analysis of the data or the writing of this report.

## **FUNDING**

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution.

## TRANSPARENCY DECLARATIONS

None to declare


## REFERENCES

1. Ait-Khaled N, Alarcón E, Armengol R *et al.* Management of tuberculosis: a guide to the essentials of good practice. Paris, France: International Union Against Tuberculosis and Lung Disease, 2010. [https://www.theunion.org/what-we-do/publications/technical/english/pub\\_orange-guide\\_eng.pdf](https://www.theunion.org/what-we-do/publications/technical/english/pub_orange-guide_eng.pdf)
2. World Health Organization. Treatment of tuberculosis: guidelines for national programmes 2003. *WHO/CDS/TB/2003313*. [https://apps.who.int/iris/bitstream/handle/10665/67890/WHO\\_CDS\\_TB\\_2003.313\\_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/67890/WHO_CDS_TB_2003.313_eng.pdf); sessionid=7925D3A063F43AEEA73E7898F421DB9D?sequence=1
3. Muliaditan M, Davies GR, Simonsson US *et al.* The implications of model-informed drug discovery and development for tuberculosis. *Drug Discov Today* 2017; **22**: 481-6.
4. Chirehwa MT, Rustomjee R, Mthiyane T *et al.* Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. *Antimicrob Agents Chemother* 2015; **60**: 487-94.
5. McIlleron H, Rustomjee R, Vahedi M *et al.* Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. *Antimicrob Agents Chemother* 2012; **56**: 3232-8.
6. Rockwood N, Meintjes G, Chirehwa M *et al.* HIV-1 coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African tuberculosis outpatients. *Antimicrob Agents Chemother* 2016; **60**: 6050-9.
7. Sahota T, Della Pasqua O. Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. *Antimicrob Agents Chemother* 2012; **56**: 5442-9.
8. Chirehwa MT, McIlleron H, Rustomjee R *et al.* Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis. *Antimicrob Agents Chemother* 2017; **61** **61(8)**. pii: e00490-17.
9. Johnston JC, Khan FA, Dowdy DW. Reducing relapse in tuberculosis treatment: is it time to reassess WHO treatment guidelines? *Int J Tuberc Lung Dis* 2015; **19**: 624.
10. Ahmad Z, Fraig MM, Bisson GP *et al.* Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. *Antimicrob Agents Chemother* 2011; **55**: 1527-32.
11. Boeree MJ, Heinrich N, Aarnoutse R *et al.* High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. *Lancet Infect Dis* 2017; **17**: 39-49.

12. Donald PR, Parkin DP, Seifart HI *et al.* The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. *Eur J Clin Pharmacol* 2007; **63**: 633-9.
13. Steingart KR, Jotblad S, Robsky K *et al.* Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. *Int J Tuberc Lung Dis* 2011; **15**: 305-16.
14. Goutelle S, Bourguignon L, Maire P *et al.* The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. *Curr Pharm Des* 2014; **20**: 6191-206.
15. Smythe W, Khandelwal A, Merle C *et al.* A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. *Antimicrob Agents Chemother* 2012; **56**: 2091-8.
16. Wilkins JJ, Langdon G, McIlhleron H *et al.* Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. *Br J Clin Pharmacol* 2011; **72**: 51-62.
17. Wilkins JJ, Langdon G, McIlhleron H *et al.* Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. *Eur J Clin Pharmacol* 2006; **62**: 727-35.
18. Jonsson S, Davidse A, Wilkins J *et al.* Population pharmacokinetics of ethambutol in South African tuberculosis patients. *Antimicrob Agents Chemother* 2011; **55**: 4230-7.
19. Holford NHG, Anderson BJ. Allometric size: The scientific theory and extension to normal fat mass. *Eur J Pharm Sci* 2017; **109S**: S59-S64.
20. Gumbo T, Louie A, Liu W *et al.* Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. *Antimicrob Agents Chemother* 2007; **51**: 2329-36.
21. Jayaram R, Gaonkar S, Kaur P *et al.* Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. *Antimicrob Agents Chemother* 2003; **47**: 2118-24.
22. Van Peer A. Variability and impact on design of bioequivalence studies. *Basic Clin Pharmacol Toxicol* 2010; **106**: 146-53.
23. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
24. Beal S, Sheiner LB, Boekmann A *et al.* NONMEM's User's Guides (ICON Development Solutions, Ellicott City, MD, USA, 2009). 2009.
25. Sinshaw Y, Alemu S, Fekadu A *et al.* Successful TB treatment outcome and its associated factors among TB/HIV co-infected patients attending Gondar University Referral Hospital, Northwest Ethiopia: an institution based cross-sectional study. *BMC Infect Dis* 2017; **17**: 132.
26. Biruk M, Yimam B, Abrha H *et al.* Treatment outcomes of tuberculosis and associated factors in an Ethiopian University Hospital. *Advances in Public Health (Article ID 8504629)* 2016; **2016**:1-9.
27. Sekaggya-Wiltshire C, von Braun A, Lamorde M *et al.* Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations. *Clin Infect Dis* 2018; **67**: 708-16.


28. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. *Annu Rev Pharmacol Toxicol* 2008; **48**: 303-32.
29. Alsultan A, Savic R, Dooley KE *et al.* Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. *Antimicrob Agents Chemother* 2017.
30. Diop AH, Gakiria G, Pande SB *et al.* Dosages of anti-tuberculosis medications in the national tuberculosis programs of Kenya, Nepal, and Senegal. *Int J Tuberc Lung Dis* 2002; **6**: 215-21.
31. Semvua HH, Kibiki GS, Kisanga ER *et al.* Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. *Ther Drug Monit* 2015; **37**: 22-32.
32. Daskapan A, Idrus LR, Postma MJ *et al.* A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. *Clin Pharmacokinet* 2018.
33. World Health Organization. Global Tuberculosis Report 2017. [https://www.who.int/tb/publications/global\\_report/gtbr2017\\_main\\_text.pdf](https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf)

## FIGURE AND TABLE LEGENDS




**Figure 1.** Density plots of the baseline demographic characteristics of the trial population (N=2231). Height distribution was available from 1833 patients only.






**Figure 2.** Comparison of simulated  $AUC_{0-24}$  at steady state following proposed adjusted dosing regimens versus regimens based WHO recommended weight band and cut-off value of 50 kg (N=2231; 200 clinical trial simulations). Box-plots depict 5<sup>th</sup>, 25<sup>th</sup>, median, 75<sup>th</sup> and 95<sup>th</sup> percentile of simulated secondary PK parameters.



**Figure 3.** Comparison of predicted relative variability in median exposure across the trial population following proposed adjusted dosing regimens (closed squares) versus regimens based WHO recommended weight band (closed circles) and cut-off value of 50 kg (closed triangles). Patients in the highest WHO weight band (>70 kg) were selected as the reference population. Dashed horizontal lines represent the variability acceptance interval (80-120%).



**Figure 4.** Predicted non-linear relationship between weight and clearance (CL/F) of the standard of care drugs in the trial population (N=2231). Closed circles represent the simulated median individual CL/F, normalized to body weight.




**Table 1.** Summary of demographic characteristics of the trial population.

|   |               |
|---|---------------|
| Age (years)   | 35 (18-65)    |
| Weight (kg)   | 58 (32-141)   |
| <i>N patients per WHO weight band (%)</i>   |               |
| <40 kg  | 46 (2.1%)     |
| 40-54 kg  | 759 (34)      |
| 55-70 kg  | 1054 (47.2)   |
| >70 kg  | 372 (16.7)    |
| <i>N patients per crude-weight band (%)</i>   |               |
| <50 kg  | 460 (21)      |
| ≥50 kg  | 1771 (79)     |
| Height (cm)*  | 168 (131-200) |
| Body mass index (kg/m <sup>2</sup> )*   | 20.3 (12-57)  |
| Male patients   | 1555 (69.6%)  |
| Data are presented as median (range) unless stated otherwise; * data available from 1833 patients |               |


**Table 2.** Proposed adjusted weight-band based dosing regimen for first-line antitubercular drugs. Under the proposed dosing regimen, 1 additional fixed-dose combination tablet was given to patients in the <40 kg (from 2 to 3) and 40-54 kg (from 3 to 4), in comparison to WHO recommendations.

| Drugs (tablet strength) | Daily dose for each weight band (no of tablets) |          |          |         |
|-------------------------|---|----------|----------|---------|
|                         | < 40 kg   | 40-54 kg | 55-70 kg | > 70 kg |
| Rifampicin (150 mg)     | 3   | 4        | 4        | 5       |
| Isoniazid (75 mg)       |   |          |          |         |
| Pyrazinamide (400 mg)   |   |          |          |         |
| Ethambutol (275 mg)     |   |          |          |         |


density



■ <40kg ■ 40-54kg ■ 55-70kg ■ >70kg



Dosing regimen  WHO  Crude  Proposed





Dosing regimen ● <40kg ● 40-54kg ● 55-70kg ● >70kg

